Severe ifosfamide-induced neurotoxicity: a case report

被引:0
作者
Sara Ramos Linares
Joaquín Breña Atienza
Matilde Cháfer Rudilla
Pablo Ríos Rull
Ana Cabello Rodríguez
Javier Merino Alonso
机构
[1] Hospital Universitario Nuestra Señora de Candelaria,Pharmacy Department
[2] Hospital Universitario Nuestra Señora de Candelaria,Hematology Department
来源
Pharmacy World & Science | 2010年 / 32卷
关键词
Ifosfamide; Neurotoxicity; Risk factors; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture. Case description We describe the case of a male with a mixed cellularity subtype classical Hodgkin’s lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy. Discussion Among the risk factors described in the literature, our patient had previously received cysplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used. Conclusion This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.
引用
收藏
页码:109 / 111
页数:2
相关论文
共 29 条
  • [1] Klatersky J(2003)Side effects of ifosfamide Oncology 65 7-10
  • [2] Rieger C(2004)Incidence and severity of ifosfamide-induced encephalopathy Anti-Cancer Drugs 15 347-350
  • [3] Fiegl M(2007)Ifosfamide encephalopathy Clin Oncol 19 108-114
  • [4] Tischer J(2007)Ifosfamide, gemcitabine, vinorelbine: a new induction regimen for refractory, relapsed Hodgkin’s lymphoma Haematologica 92 35-41
  • [5] Ostermann H(2003)Pharmacology of Ifosfamide Oncology 65 2-6
  • [6] Schiel X(2006)Methylene blue for management of ifosfamide-induced encephalopathy Ann Pharmacother 40 299-303
  • [7] Ajithkumar T(2005)Evaluating risk factors for the development of ifosfamide encephalopathy Am J Clin Oncol 28 277-280
  • [8] Parkinson C(2006)Role of thiamine in managing ifosfamide-induced encephalopathy J Oncol Pharm Pract 2 299-303
  • [9] Shamshad F(2000)Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature Br J Cancer 82 291-294
  • [10] Murray P(undefined)undefined undefined undefined undefined-undefined